Sugi Predict

Sugi Predict / Compounds / SCHEMBL12074841

SCHEMBL12074841

SCHEMBL12074841

CC(C)c1cc(N2CCCC2)ccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 2/20 0.47
▸ MAPT P10636 6/20 0.41
▸ ALDH1A1 P00352 6/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ ALOX15 P16050 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ TERT O14746 3/20 0.41
▸ CYP1A2 P05177 2/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ TNF P01375 2/20 0.40
▸ S100B P04271 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ HTT P42858 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25150431 0.86 HIF1A (0.43) HIF1AMAPTALDH1A1MEN1ALOX15
SCHEMBL24595076 0.84 HIF1A (0.46) HIF1AMAPTALDH1A1MEN1ALOX15
SCHEMBL13326992 0.83 HIF1A (0.43) HIF1AMAPTALDH1A1MEN1ALOX15
SCHEMBL12806643 0.79 HSP90AB1 (0.43) MAPTALDH1A1MEN1ALOX15KMT2A
SCHEMBL2933216 0.77 LMNA (0.51) MAPTALDH1A1MEN1ALOX15KMT2A
SCHEMBL24595079 0.76 HPGD (0.49) MAPTALDH1A1MEN1ALOX15KMT2A
SCHEMBL13913523 0.76 ALDH1A1 (0.54) HIF1AMAPTALDH1A1MEN1KMT2A
SCHEMBL28209205 0.76 TRIM24 (0.41) HIF1AMAPTALDH1A1MEN1ALOX15
SCHEMBL12176444 0.76 HPGD (0.51) MAPTALDH1A1MEN1ALOX15KMT2A
SCHEMBL19998610 0.76 HPGD (0.47) MAPTALDH1A1MEN1ALOX15KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230102258-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2023-03-30 — — US disclosed
US-20230043159-A1 MATRIPTASE 2 INHIBITORS AND USES THEREOF DISC MEDICINE, INC. 2023-02-09 — — US disclosed
US-10035768-B2 C5aR antagonists CHEMOCENTRYX, INC. (US) 2018-07-31 — — US disclosed
US-20180179160-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2018-06-28 — — US disclosed
US-20180179160-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2018-06-28 — — US disclosed
US-20170114017-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2017-04-27 — — US disclosed
US-20170065604-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. 2017-03-09 — — US disclosed
US-9573897-B2 C5AR antagonists CHEMOCENTRYX, INC. (US) 2017-02-21 — — US disclosed
US-9573897-B2 C5AR antagonists CHEMOCENTRYX, INC. (US) 2017-02-21 — — US disclosed
WO-2017023905-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA BRISTOL-MYERS SQUIBB COMPANY (US) 2017-02-09 — — WO disclosed
US-8906938-B2 C5aR antagonists CHEMOCENTRYX, INC. (US) 2014-12-09 — — US disclosed
US-20130172347-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2013-07-04 — — US disclosed
US-8445515-B2 C5aR antagonists CHEMOCENTRYX, INC. (US) 2013-05-21 — — US disclosed
WO-2011163640-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2011-12-29 — — WO disclosed
US-20110275639-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2011-11-10 — — US disclosed
US-20110275639-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2011-11-10 — — US disclosed
US-20100311753-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2010-12-09 — — US disclosed
US-20100311753-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2010-12-09 — — US disclosed
WO-2010075257-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2010-07-01 — — WO disclosed
US-20100160320-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2010-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160320-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 HIF1A 1708/4885MAPT 4107/4885ALDH1A1 2966/4885
US-20110275639-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 HIF1A 1708/4885MAPT 4107/4885ALDH1A1 2966/4885
US-20170114017-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 HIF1A 1708/4885MAPT 4107/4885ALDH1A1 2966/4885
US-20180179160-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 HIF1A 1708/4885MAPT 4107/4885ALDH1A1 2966/4885
US-10035768-B2 C5aR antagonists C5AR1, C5AR2, C3AR1 HIF1A 1708/4885MAPT 4107/4885ALDH1A1 2966/4885
US-20230102258-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 HIF1A 1708/4885MAPT 4107/4885ALDH1A1 2966/4885
US-20100311753-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 HIF1A 1708/4885MAPT 4107/4885ALDH1A1 2966/4885
US-20130172347-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 HIF1A 1708/4885MAPT 4107/4885ALDH1A1 2966/4885
US-20230043159-A1 MATRIPTASE 2 INHIBITORS AND USES THEREOF MMP7, MATR3, SPINT2 HIF1A 2340/4885MAPT 1700/4885ALDH1A1 3877/4885
US-20170065604-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 HIF1A 1772/4885MAPT 4239/4885ALDH1A1 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.